Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Notes Payables (2016 - 2017)

Editas Medicine (EDIT) has disclosed Notes Payables for 2 consecutive years, with $7.5 million as the latest value for Q4 2017.

  • On a quarterly basis, Notes Payables fell 25.0% to $7.5 million in Q4 2017 year-over-year; TTM through Dec 2017 was $7.5 million, a 25.0% decrease, with the full-year FY2017 number at $7.5 million, down 25.0% from a year prior.
  • Notes Payables was $7.5 million for Q4 2017 at Editas Medicine, down from $15.0 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $15.0 million in Q1 2017 to a low of $7.5 million in Q4 2017.